lung cancer | |||||
新闻 | |||||
Evaluating the Cost-Effectiveness of NSCLC Treatments: New Insights From a Recent Review Non-small cell lung cancer (NSCLC) is a major driver of economic strain on healthcare sysh tems worldwide due to its high treatment costs.
| |||||
Chugai Wins the MHLW Minister's Award at the Seventh Japan Medical Research and ... ALK-positive lung cancer is said to account for approximately 3-5% of non-small cell lung cancers1. In Japan, Alecensa has also been approved for the ...
| |||||
In case you missed it: This week's Top 5 stories on social media - Mayo Clinic News Network Keith Knutson, a cancer vaccine researcher at Mayo Clinic, explains how the development of personalized lung cancer vaccines is giving hope to ...
| |||||
查看更多结果 | 修改此快讯 |
您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
发送反馈 |
No comments:
Post a Comment